

LIST OF REFERENCES CITED BY APPLICANT

(Use Several Sheets if Necessary)

DOCKET NO.: 3991/OK379
APPLICANT: Mark Andrew GUTHRIDGESERIAL NO: t/b/a
FILING DATE: Concurrently Herewith
CONFIRMATION NO:31003 U.S. PTO
10/099895
03/14/83**U.S. PATENT DOCUMENTS**

*EXAMINER INITIALS	NUMBER	DOCUMENT DATE	NAME	CLASS	SUBCLASS	FILING DATE
-----------------------	--------	------------------	------	-------	----------	-------------

FOREIGN PATENT DOCUMENTS

*EXAMINER INITIALS	NUMBER	DOCUMENT DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
-----------------------	--------	------------------	---------	-------	----------	-----------------------

OTHER REFERENCES

(INCLUDING AUTHOR, TITLE DATE, PERTINENT PAGES, ETC.)

*EXAMINER INITIALS	
-----------------------	--

1. The Journal of Biological Chemistry, Vol 269 No: 42 (1994) pages 26259-26266 (LEWIS, R. et al) "Phorbol Ester Stimulates Phosphorylation on Serine 1327 of the Human Insulin Receptor"
2. The Journal of Biological Chemistry Vol 268 No: 9 (1993) pages 6765-6770 (MERIDA, I et al) "The Serine-rich Cytoplasmic Domain of the Interleukin-2 Receptor β Chain is Essential for Interleukin-dependent Tyrosine Protein Kinase and Phosphatidylinositol-3 kinase Activation"
3. The Journal of Biological Chemistry, Vol 273 No: 16 (1998) pages 9365-9368 (CHARNG, MIN-JI et al) "A Novel Protein Distinguishes between Quiescent and Activated Forms of the Type I Transforming Growth Factor β Receptor"
4. The Journal of Biological Chemistry Vol 269 No: 3 (1994) pages 1815-1820 (GANDINO, L. et al) "Phosphorylation of Serine 985 Negatively Regulates the Hepatocyte Growth Factor Receptor Kinase"

Zach Howard

5/2/05

LIST OF REFERENCES CITED BY APPLICANT

(Use Several Sheets if Necessary)

DOCKET NO.: 3991/OK379
APPLICANT: Mark Andrew GUTHRIDGESERIAL NO: t/b/a
FILING DATE: Concurrently Herewith
CONFIRMATION NO:***EXAMINER
INITIALS**

- 3H 5. EMBO Journal Vol 8 No: 10 (1989) pages 2955-2965 (FREED, E et al) "A Novel Integrin β Integrin Subunit is Associated with the Vitronectin Receptor α subunit (α) in a Human Osteosarcoma Cell Line and is a Substrate for Protein Kinase C"
- 3H 6. Journal of Biotechnology Vol 37 (1994) pages 109-122 (BARDELLI, A et al) "Identification of Functional Domains in the Hepatocyte Growth Factor and its Receptor by Molecular Engineering"
- 3H 7. The Biochemical Journal Vol 235 No: 1 (1986) pages 1-11 (GAMMELTOFT, S et al) "Protein Kinase Activity of the Insulin Receptor"
- 3H 8. Stem Cells, Vol 16, No: 5 (1998) pages 301-313 (GUTHRIDGE, MA et al) "Mechanism of Activation of the GM-CSF, IL-3, and IL-5 family of Receptors"
- 3H 9. The Journal of Biological Chemistry, Vol 274 No: 47 (199) pages 33474-33479 (BONDAR, RJ et al) "The Cytoplasmic Domain of the Platelet Glycoprotein Iba α is Phosphorylated at serine 609"
- 3H 10. Blood, Vol 95 No: 2 (2000) pages 551-557 (FENG S, et al) "Cytoplasmic Domains of Gplb α and Gplb β regulate 14-3-3 ζ Binding to Gp1B/IX/V"
- 3H 11. Blood, Vol 94 No: 6 (1999) pages 1933-1942 (STOMSKI, F C et al) "Identification of a 14-3-3 Binding Sequence in the Common β Chain of the Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), Interleukin-3 (IL-3), and I-5 Receptors That is Serine-Phosphorylated by GM-CSF"

EXAMINER:

Josh Howard

DATE CONSIDERED:

5/2/05

* **EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/099,895		
		Filing Date	March 14, 2002		
		First Named Inventor	Mark A. Guthridge		
		Art Unit	1645		
		Examiner Name	Not Yet Assigned		
Sheet	1	of	2	Attorney Docket Number	03991/000K379-USO

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
3H	1	WO-92 01788-A1	02-06-1992	Schering Corp.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²		
3H	2	DATABASE SWISSPROT 'Online! Cytokine receptor common beta chain precursor, 1 October 1993, Database accession no. p32927, XP002238516			
3H	3	GONDA THOMAS J ET AL: "Activating mutations in cytokine receptors: Implications for receptor function and role in disease.", BLOOD, vol. 89, no. 2, 1997, pages 355-369, XP002238511			
3H	4	MUSLIN A J ET AL: "Interaction of 14-3-3 with signaling proteins is mediated by the recognition of phosphoserine", CELL, CELL PRESS, Cambridge, MA, US, vol. 84, 22 March 1996, pages 889-897, XP002089347			
3H	5	BAGLEY C J ET AL: "The Structural And Functional Basis of Cytokine Receptor Activation: Lessons From The Common Beta Subunit of the Granulocyte-Macrophage Colony-Stimulating Factor, Interleukins-3 (IL-3), And IL-5 Receptors", BLOOD, W.B. SAUNDERS, Philadelphia, PA, US, vol. 89, no. 5, 1 March 1997, pages 1471-1482, XP 001052641			
3H	6	DE GROOT ROLF P ET AL: "Regulation of Proliferation, differentiation and survival by the IL-3/IL-5/GM-CSF receptor family", CELLULAR SIGNALLING, vol. 10, no. 9, October 1998, pages 619-628, XP002238512			
3H	7	JUCKER MANFRED ET AL: "Identification of a new adapter protein that may link the common beta subunit of the receptor for granulocyte/macrophage colony-stimulating factor, interleukin (IL)-3, and IL-5 to phosphatidylinositol 3- kinase", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 46, 1995, pages 27817-27822, XP002238513			
3H	8	SMITH ALISON ET AL: "Cytoplasmic domains of the common beta-chain of the GM-CSF/IL-3/IL-5 receptors that are required for inducing differentiation or clonal suppression in myeloid leukaemic cell lines", EMBO (EUROPEAN MOLECULAR BIOLOGY ORGANIZATION) JOURNAL, vol. 16, no. 3, 1997, pages 451-464, XP002238514			
3H	9	SAKAMAKI K ET AL: "Critical Cytoplasmic Domains of the Common Beta Subunit of the Human GM-CSF, IL-3 and IL-5 Receptors For Growth Signal Transduction and Tyrosine Phosphorylation"; EMBO JOURNAL, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 11, no. 10, 1992, pages 3541-3549, XP002070273			
3H	10	LIU Y-C ET AL: "Serine phosphorylation of Cbl induced by phorbol ester enhances its association with 14-3-3 proteins in T cells via a novel serine-rich 14-3-3-binding motif",			

Examiner Signature	<i>Zach Howard</i>	Date Considered	5/2/05
-----------------------	--------------------	--------------------	--------

continues
on
next
page



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/099,895
				Filing Date	March 14, 2002
				First Named Inventor	Mark A. Guthridge
				Art Unit	1645
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	03991/000K379-USO
Sheet	2	of	2		

37		JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 272, no. 15, 11 April 1997, pages 9979-9985, XP002089346	/
34	11	SUN Q ET AL: "Simultaneous antagonism of interleukin-5, granulocyte-macrophage colony-stimulating factor, and interleukin-3 stimulation of human eosinophils by targetting the common cytokine binding site of their receptors", BLOOD, vol. 94, no. 6, pages 1943-1951, XP002238515	/

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	<i>Zach Howard</i>	Date Considered	5/2/05
-----------------------	--------------------	--------------------	--------



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Application Number	10/099,895-Conf. #5422	
			Filing Date	March 14, 2002	
			First Named Inventor	Mark A. Guthridge	
			Art Unit	1645	
			Examiner Name	Not Yet Assigned	
Sheet	1	of	2	Attorney Docket Number	03991/000K379-USO

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	1	US-5,677,144-B1	10-14-1997	Ullrich et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
ZH	2	WO-97/48728-A1	12-24-1997	Van Leengoed et al.		-

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ²
ZH	3	ZHANG SHAO-HUI ET AL.: "Serine phosphorylation-dependent association of the band 4.1-related protein-tyrosine phosphatase PTPH1 with 14-3-3-beta protein"; JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 43, 1997, pages 27281-27287, XP002267717.				
ZH	4	BONNEFOY-BERARD NATHALIE ET AL.: "Inhibition of phosphatidylinositol 3-kinase activity by association with 14-3-3 proteins in T cells"; PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 92, no. 22, 1995, pages 10142-10146, XP002267718.				
ZH	5	HIBI M ET AL.: "MOLECULAR CLONING AND EXPRESSION OF AN IL-6 SIGNAL TRANSDUCER, GP130"; CELL, CELL PRESS, CAMBRIDGE, MA, US, vol. 63, 21 December 1990, pages 1149-1157, XP001073990.				
ZH	6	DATABASE UNIPROT [Online] IL-6R-beta; IL-6 signal transducer gp130, 1 February 1995, XP002267721, Database accession no. P40189.				
ZH	7	MURAKAMI M ET AL.: "Critical cytoplasmic region of the interleukin 6 signal transducer gp130 is conserved in the cytokine receptor family"; PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCE, WASHINGTON, US, vol. 88, December 1991, pages 11349-11353, XP002954109.				
ZH	8	TARTAGLIA L A ET AL.: "IDENTIFICATION AND EXPRESSION CLONING OF A LEPTIN RECEPTOR, OB-R"; CELL, CELL PRESS, CAMBRIDGE, MA, US, vol. 83, no. 7, 29 December 1995, pages 1263-1271, XP000602068.				
ZH	9	DATABASE UNIPROT [Online], Leptin receptor precursor (LEP-R, OB-R) 1 February 1996, XP002267722, Database accession no. P48357.				
ZH	10	LI CAI ET AL.: "Leptin receptor activation of SH2 domain containing protein tyrosine phosphatase 2 modulates Ob receptor signal transduction"; PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY SCIENCE, WASHINGTON, US, vol. 96, no. 17, 17 August 1999, pages 9677-9682, XP002185670.				
ZH	11	SMITH C A ET AL.: "A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins"; SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, vol. 248, 25 May 1990, pages 1019-1022, XP002107350.				
ZH	12	DATABASE UNIPROT [Online] TNF-R2, p75 1 February 1995, XP002267723, Database				

Examiner Signature	Zach Howard	Date Considered	5/2/05
-----------------------	-------------	--------------------	--------

→ continues on
next page



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/099,895-Conf. #5422		
		Filing Date	March 14, 2002		
		First Named Inventor	Mark A. Guthridge		
		Art Unit	1645		
		Examiner Name	Not Yet Assigned		
Sheet	2	of	2	Attorney Docket Number	03991/000K379-US0

3H	—	accession no. P20333.	—
3H	—	13 NG PATRICK W P ET AL.: "Mutations which abolish phosphorylation of the TRAF-binding domain of the TNF receptor 2 enhance receptor-mediated NF-kappaB activation": BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS; vol. 244, no. 3, 27 March 1998, pages 756-762, XP002267719.	
3H	—	14 DARNAY B G ET AL.: "The p80TNF receptor-associated kinase (p80TRAK) associates with residues 354-397 of the p80 cytoplasmic domain: similarity to casein kinase": FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL., vol. 406, no. 1-2, 7 April 1997, pages 101-105, XP004261192.	
3H	—	15 SHIBUYA M ET AL.: "NUCLEOTIDE SEQUENCE AND EXPRESSION OF A NOVEL HUMAN RECEPTOR-TYPE, TYROSINE KINASE GENE (FLT) CLOSELY RELATED TO THE FMS FAMILY"; ONCOGENE, BASINGSTOKE, HANTS, GB, vol. 5, 1990, pages 519-524, XP000569874.	
3H	—	16 DATABASE UNIPROT [Online] VGr1 (VEGR1 or FLT) 1 November 1990, XP002267724, Database accession no. P17948.	
3H	—	17 GERBER HANS-PETER ET AL.: "Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway: Requirement for Flk-1KDR activation"; JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US., vol. 273, no. 46, 13 November 1998, pages 30336-30343, XP002155564.	
3H	—	18 KARN T ET AL.: "STRUCTURE, EXPRESSION AND CHROMOSOMAL MAPPING OF TKT FROM MAN AND MOUSE: A NEW SUBCLASS OF RECEPTOR TYROSINE KINASES WITH A FACTOR VIII-LIKE DOMAIN"; ONCOGENE, BASINGSTOKE, HANTS, GB, vol. 8, no. 12, 1 December 1993, pages 3433-3440, XP000471876.	
3H	—	19 DATABASE SWISSPROT [Online] Receptor protein tyrosine kinase (TKT; DDR2), 1 November 1997, XP002267725, Database accession no. Q16832.	
3H	—	20 MASIAKOWSKI PIOTR ET AL.: "A novel family of cell surface receptors with tyrosine kinase-like domain"; JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 267, no. 36, 1992, pages 26181-26190, XP002267720.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	Zach Howard	Date Considered	5/2/05
--------------------	-------------	-----------------	--------